Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study

The Lancet Neurology

Volumn 15, Issue 10, 2016, Pages 1035-1043

  Kunz, Alexander ^a   Ebinger, Martin ^a   Geisler, Frederik ^a   Rozanski, Michal ^a   Waldschmidt, Carolin ^a   Weber, Joachim E ^a   Wendt, Matthias ^a   Winter, Benjamin ^a   Zieschang, Katja ^a   Fiebach, Jochen B ^a   Villringer, Kersten ^a   Erdur, Hebun ^a   Scheitz, Jan F ^a   Tütüncü, Serdar ^a   Bollweg, Kerstin ^a   Grittner, Ulrike ^a   Kaczmarek, Sabina ^b   Endres, Matthias ^a,c   Nolte, Christian H ^a   Audebert, Heinrich J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berliner Feuerwehr   (Germany)

^c BERLIN INSTITUTE OF HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AMBULANCE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL OUTCOME; EMERGENCY CARE; FEMALE; FIBRINOLYTIC THERAPY; HOSPITAL CARE; HOSPITAL MORTALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANKIN SCALE; REGISTER; STROKE PATIENT; CLINICAL TRIAL; COMPARATIVE STUDY; HOSPITALIZATION; MIDDLE AGED; PREVENTIVE HEALTH SERVICE; STATISTICS AND NUMERICAL DATA; STROKE;

AGED; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MOBILE HEALTH UNITS; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84991083791     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30129-6     Document Type: Article

References (27)

1. 1 Emberson, J, Lees, KR, Lyden, P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384 (2014), 1929–1935.
2. 2 Hacke, W, Kaste, M, Bluhmki, E, et al. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 359 (2008), 1317–1329.
3. 3 Lansberg, MG, Schrooten, M, Bluhmki, E, Thijs, VN, Saver, JL, Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the Modified Rankin Scale. Stroke 40 (2009), 2079–2084.
4. 4 Lees, KR, Bluhmki, E, von Kummer, R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375 (2010), 1695–1703.
5. 5 Marler, JR, Tilley, BC, Lu, M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 55 (2000), 1649–1655.
6. 6 Sandercock, P, Wardlaw, JM, Lindley, RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379 (2012), 2352–2363.
7. 7 Wahlgren, N, Ahmed, N, Davalos, A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007), 275–282.
8. 8 Fonarow, GC, Smith, EE, Saver, JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 123 (2011), 750–758.
9. 9 Saver, JL, Fonarow, GC, Smith, EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 309 (2013), 2480–2488.
10. 10 Meretoja, A, Strbian, D, Mustanoja, S, Tatlisumak, T, Lindsberg, PJ, Kaste, M, Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 79 (2012), 306–313.
11. 11 Kohrmann, M, Schellinger, PD, Breuer, L, et al. Avoiding in hospital delays and eliminating the three-hour effect in thrombolysis for stroke. Int J Stroke 6 (2011), 493–497.
12. 12 Walter, S, Kostopoulos, P, Haass, A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol 11 (2012), 397–404.
13. 13 Ebinger, M, Rozanski, M, Waldschmidt, C, et al. PHANTOM-S: the prehospital acute neurological therapy and optimization of medical care in stroke patients—study. Int J Stroke 7 (2012), 348–353.
14. 14 Ebinger, M, Winter, B, Wendt, M, et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA 311 (2014), 1622–1631.
15. 15 Ebinger, M, Kunz, A, Wendt, M, et al. Effects of golden hour thrombolysis: a Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) substudy. JAMA Neurol 72 (2015), 25–30.
16. 16 Weber, JE, Ebinger, M, Rozanski, M, et al. Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology 80 (2013), 163–168.
17. 17 Ebinger, M, Kufner, A, Galinovic, I, et al. Fluid-attenuated inversion recovery images and stroke outcome after thrombolysis. Stroke 43 (2012), 539–542.
18. 18 Ebinger, M, Lindenlaub, S, Kunz, A, et al. Prehospital thrombolysis: a manual from Berlin. J Vis Exp, 81, 2013, e50534.
19. 19 Koch, PM, Kunz, A, Ebinger, M, et al. Influence of distance to scene on time to thrombolysis in a specialized stroke ambulance. Stroke, 2016, 10.1161/STROKEAHA.116.013057 published online June 21.
20. 20 Gerischer, LM, Fiebach, JB, Scheitz, JF, Audebert, HJ, Endres, M, Nolte, CH, Magnetic resonance imaging-based versus computed tomography-based thrombolysis in acute ischemic stroke: comparison of safety and efficacy within a cohort study. Cerebrovasc Dis 35 (2013), 250–256.
21. 21 Tutuncu, S, Ziegler, AM, Scheitz, JF, et al. Severe renal impairment is associated with symptomatic intracerebral hemorrhage after thrombolysis for ischemic stroke. Stroke 44 (2013), 3217–3219.
22. 22 Nolte, CH, Malzahn, U, Kuhnle, Y, Ploner, CJ, Muller-Nordhorn, J, Mockel, M, Improvement of door-to-imaging time in acute stroke patients by implementation of an all-points alarm. J Stroke Cerebrovasc Dis 22 (2013), 149–153.
23. 23 Rankin, J, Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 2 (1957), 200–215.
24. 24 Farrell, B, Godwin, J, Richards, S, Warlow, C, The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991), 1044–1054.
25. 25 Fonarow, GC, Zhao, X, Smith, EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 311 (2014), 1632–1640.
26. 26 Amt für Statistik Berlin-Brandenburg, Germany. Regionaler Sozialbericht Berlin-Brandenburg 2013, 2013, Amt für Statistik Berlin-Brandenburg, Potsdam, Germany.
27. 27 Wahlgren, N, Ahmed, N, Davalos, A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372 (2008), 1303–1309.